Q-Line Biotech
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
May 21 to May 25 2026
Price Band
₹326 - 343
Current GMP
₹452.0 (+31.78%)
Subscription
102.42 times
IPO Details
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | Fri, May 29, 2026 |
| Face Value | ₹ 10 per share |
| Price Band | ₹326 to ₹343 |
| Issue Price | ₹343 per share |
| Lot Size | 400 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 62,53,200 shares (agg. up to ₹ 214 Cr) |
| Reserved for Market Maker | 3,13,200 shares (agg. up to ₹ 11 Cr) Hem Finlease Pvt.Ltd. |
| Fresh Issue (Ex Market Maker) | 59,40,000 shares (agg. up to ₹ 204 Cr) |
| Net Offered to Public | 59,40,000 shares (agg. up to ₹ 204 Cr) |
| Share Holding Pre Issue | 1,70,74,999 shares |
| Share Holding Post Issue | 2,33,28,199 shares |
| / NSE Symbol | / QLINE |
| ISIN | INE1G2W01011 |
IPO Date
21 to 25 May, 2026
Listing Date
Fri, May 29, 2026
Face Value
₹ 10 per share
Price Band
₹326 to ₹343
Issue Price
₹343 per share
Lot Size
400 Shares
Sale Type
Fresh capital only
Issue Type
Bookbuilding IPO
Listing At
NSE SME
Total Issue Size
62,53,200 shares (agg. up to ₹ 214 Cr)
Reserved for Market Maker
3,13,200 shares (agg. up to ₹ 11 Cr) Hem Finlease Pvt.Ltd.
Fresh Issue (Ex Market Maker)
59,40,000 shares (agg. up to ₹ 204 Cr)
Net Offered to Public
59,40,000 shares (agg. up to ₹ 204 Cr)
Share Holding Pre Issue
1,70,74,999 shares
Share Holding Post Issue
2,33,28,199 shares
/ NSE Symbol
/ QLINE
ISIN
INE1G2W01011
IPO Subscription Details
| Anchor | 1 |
| Market Maker | 1 |
| QIB (Ex Anchor) | 123.94 |
| NII*** | 145.98 |
| bNII (> ₹10L) | 178.29 |
| sNII (< ₹10L) | 81.35 |
| Individual Investors | 71.44 |
| Total ** | 102.42 |
Anchor
1
Market Maker
1
QIB (Ex Anchor)
123.94
NII***
145.98
bNII (> ₹10L)
178.29
sNII (< ₹10L)
81.35
Individual Investors
71.44
Total **
102.42
Day Wise Sub
| Day | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| May 2 1 (Day 1) | 4.15 | 5.26 | 5.85 | 4.08 | 3.71 | 4.17 |
| May 2 2 (Day 2) | 5.19 | 15.62 | 17.96 | 10.95 | 10.07 | 9.87 |
| May 2 5 (Day 3) | 123.94 | 145.98 | 178.29 | 81.35 | 71.44 | 102.42 |
DayMay 2
1 (Day 1)
QIB (Ex Anchor)4.15
NII*5.26
NII (> ₹10L)5.85
NII (< ₹10L)4.08
Individual Investors3.71
Total4.17
DayMay 2
2 (Day 2)
QIB (Ex Anchor)5.19
NII*15.62
NII (> ₹10L)17.96
NII (< ₹10L)10.95
Individual Investors10.07
Total9.87
DayMay 2
5 (Day 3)
QIB (Ex Anchor)123.94
NII*145.98
NII (> ₹10L)178.29
NII (< ₹10L)81.35
Individual Investors71.44
Total102.42
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 29-05-2026 | 343.00 | 133(38.78%) | 476 |
| 28-05-2026 | 343.00 | 129(37.61%) | 472 |
| 27-05-2026 | 343.00 | 124(36.15%) | 467 |
| 26-05-2026 | 343.00 | 108(31.49%) | 451 |
| 25-05-2026 | 343.00 | 101(29.45%) | 444 |
| 24-05-2026 | 343.00 | 125(36.44%) | 468 |
| 23-05-2026 | 343.00 | 127(37.03%) | 470 |
| 22-05-2026 | 343.00 | 127(37.03%) | 470 |
| 21-05-2026 | 343.00 | 117(34.11%) | 460 |
| 20-05-2026 | 343.00 | 141(41.11%) | 484 |
| 19-05-2026 | 343.00 | 110(32.07%) | 453 |
| 18-05-2026 | 343.00 | 69(20.12%) | 412 |
| 17-05-2026 | 0(%) | (%) |
Date29-05-2026
Price343.00
GMP133(38.78%)
Estimate List Price476
Date28-05-2026
Price343.00
GMP129(37.61%)
Estimate List Price472
Date27-05-2026
Price343.00
GMP124(36.15%)
Estimate List Price467
Date26-05-2026
Price343.00
GMP108(31.49%)
Estimate List Price451
Date25-05-2026
Price343.00
GMP101(29.45%)
Estimate List Price444
Date24-05-2026
Price343.00
GMP125(36.44%)
Estimate List Price468
Date23-05-2026
Price343.00
GMP127(37.03%)
Estimate List Price470
Date22-05-2026
Price343.00
GMP127(37.03%)
Estimate List Price470
Date21-05-2026
Price343.00
GMP117(34.11%)
Estimate List Price460
Date20-05-2026
Price343.00
GMP141(41.11%)
Estimate List Price484
Date19-05-2026
Price343.00
GMP110(32.07%)
Estimate List Price453
Date18-05-2026
Price343.00
GMP69(20.12%)
Estimate List Price412
Date17-05-2026
Price
GMP0(%)
Estimate List Price(%)
IPO Important Dates
| IPO Open | Thu, May 21, 2026 |
| IPO Close | Mon, May 25, 2026 |
| Allotment | Tue, May 26, 2026 |
| Refund | Wed, May 27, 2026 |
| Credit of Shares | Wed, May 27, 2026 |
| Listing | Fri, May 29, 2026 |
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Allotment
Tue, May 26, 2026
Refund
Wed, May 27, 2026
Credit of Shares
Wed, May 27, 2026
Listing
Fri, May 29, 2026
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 800 | ₹2,74,400 |
| Individual investors (Retail) (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1,200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2,800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3,200 | ₹10,97,600 |
ApplicationIndividual investors (Retail) (Min)
Lots2
Shares800
Amount₹2,74,400
ApplicationIndividual investors (Retail) (Max)
Lots2
Shares800
Amount₹2,74,400
ApplicationS-HNI (Min)
Lots3
Shares1,200
Amount₹4,11,600
ApplicationS-HNI (Max)
Lots7
Shares2,800
Amount₹9,60,400
ApplicationB-HNI (Min)
Lots8
Shares3,200
Amount₹10,97,600
Financial Information
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | 229.16 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 212.89 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Period EndedAssets
31 Dec 2025561.34
31 Mar 2025455.49
31 Mar 2024339.25
31 Mar 2023251.58
Period EndedTotal Income
31 Dec 2025236.50
31 Mar 2025322.58
31 Mar 2024206.45
31 Mar 2023184.81
Period EndedProfit After Tax
31 Dec 202538.69
31 Mar 202528.13
31 Mar 202434.44
31 Mar 202332.10
Period EndedEBITDA
31 Dec 202564.23
31 Mar 202571.32
31 Mar 202437.63
31 Mar 202332.98
Period EndedNET Worth
31 Dec 2025229.16
31 Mar 2025189.95
31 Mar 2024161.81
31 Mar 2023127.37
Period EndedReserves and Surplus
31 Dec 2025212.89
31 Mar 2025188.37
31 Mar 2024160.24
31 Mar 2023125.79
Period EndedTotal Borrowing
31 Dec 2025243.85
31 Mar 2025164.95
31 Mar 202496.91
31 Mar 202373.65
Key Performance Indicator
| ROE | 16.88% |
| ROCE | 13.32% |
| Debt/Equity | 1.06 |
| RoNW | 16.88% |
| PAT Margin | 16.65% |
| EBITDA Margin | 27.64% |
| Price to Book Value | 2.44 |
ROE
16.88%
ROCE
13.32%
Debt/Equity
1.06
RoNW
16.88%
PAT Margin
16.65%
EBITDA Margin
27.64%
Price to Book Value
2.44
IPO Reservation
| QIB Shares Offered | 29,69,200 |
| − Anchor Investor Shares Offered | 17,81,200 |
| − QIB (Ex. Anchor) Shares Offered | 11,88,000 |
| NII (HNI) Shares Offered | 8,91,600 |
| − bNII > ₹10L | 5,94,400 |
| − sNII < ₹10L | 2,97,200 |
| Retail Shares Offered | 20,79,200 |
| Market Maker Shares Offered | 3,13,200 |
| Total Shares Offered | 62,53,200 |
QIB Shares Offered
29,69,200
− Anchor Investor Shares Offered
17,81,200
− QIB (Ex. Anchor) Shares Offered
11,88,000
NII (HNI) Shares Offered
8,91,600
− bNII > ₹10L
5,94,400
− sNII < ₹10L
2,97,200
Retail Shares Offered
20,79,200
Market Maker Shares Offered
3,13,200
Total Shares Offered
62,53,200
Information about company
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As on March 31, 2026, the company had 362 permanent employees.
Competitive Strengths :
Objectives of IPO
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
#: Issue Objects
1: To meet working capital requirements
2: Repayment of certain borrowing availed by the Company, in part or full
3: General Corporate Purposes
: Total
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App